在大血管封闭症中使用类似葡萄糖-1受体激动剂,通过再输疗法治疗 - 一个2期随机试验
Hao Wang1, Ho Ko2,3,4, Thomas W Leung5,6,7,8
1Department of Neurology, Linyi People's Hospital, Affiliated Hospital of Shandong Second Medical University, Linyi, China.
Nature communications
|December 14, 2025
概括
在接受内血管治疗 (EVT) 的急性大血管封闭 (LVO) 患者中,塞马格卢提德显示安全性. 它可能会改善那些没有接受静脉血栓溶解 (IVT) 的人的神经结果.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性大血管封闭 (LVO) 中风需要及时的内血管治疗 (EVT).
- 优化EVT后的神经恢复是一个关键的临床挑战.
- 研究新的治疗药物,如用于中风管理的西马格卢提德是必不可少的.
研究的目的:
- 评估在接受EVT的急性LVO患者中塞马格卢提德的疗效和安全性.
- 为了确定塞马格卢提德是否与标准治疗相比改善神经恢复.
- 探索潜在的治疗效果修改,例如静脉输血栓溶解 (IVT).
主要方法:
- 第二阶段,随机化,开放标签,盲目的终点试验在中国.
- 140名患有致残性LVO,接受EVT的患者被随机分配到semaglutide或标准治疗.
- 主要结局:有利的神经恢复 (修改的兰金尺度0-2在90天).
主要成果:
- 总体而言,semaglutide和标准治疗组之间主要结局没有显著差异 (56.5%与54.9%对比).
- 与静脉输血栓溶解 (IVT) 观察到一个显著的相互作用 (p=0.02).
- 在没有IVT的小组中,塞马格卢提德呈现了改善结果的趋势 (64.7%与44.1%相比).
- 塞马格卢提德是安全的,没有严重的不良事件归因于治疗.
结论:
- 对于接受EVT的LVO患者来说,塞马格卢提德是安全的.
- 初步发现表明,在不接受静脉输血治疗的患者中,塞马格卢提德可能有好处.
- 需要在第三期随机试验中进一步证实这些探索性结果的有效性.
更多相关视频
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.6K
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
3.7K
相关概念视频
01:24Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
01:27Peripheral Artery Disease III: Interprofessional Care
221
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
221